Pharmacotherapeutic management of lower urinary tract symptoms in Multiple Sclerosis patients

References

• Reich DS , Lucchinetti CF , Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169–180.
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444–1452.
   PubMed Web of Science ®Google Scholar
• Khalaf KM , Coyne KS , Globe DR , et al. Lower urinary tract symptom prevalence and management among patients with multiple sclerosis. Int J MS Care. 2015;17(1):14–25.
   PubMedGoogle Scholar
• Amarenco G , Chartier-Kastler E , Denys P , et al. First-line urological evaluation in multiple sclerosis: validation of a specific decision-making algorithm. Mult Scler. 2013;19(14):1931–1937.
   PubMed Web of Science ®Google Scholar
• Fowler CJ , Panicker JN , Drake M , et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(5):470–477.
   PubMed Web of Science ®Google Scholar
• Tubaro A , Puccini F , De Nunzio C , et al. The treatment of lower urinary tract symptoms in patients with multiple sclerosis: a systematic review. Curr Urol Rep. 2012;13(5):335–342.
   PubMed Web of Science ®Google Scholar
• Nortvedt MW , Riise T , Frugard J , et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to five years after diagnosis. Mult Scler. 2007;13(1):106–112.
   PubMed Web of Science ®Google Scholar
• Vitkova M , Rosenberger J , Krokavcova M , et al. Health-related quality of life in multiple sclerosis patients with bladder, bowel and sexual dysfunction. Disabil Rehabil. 2014;36(12):987–992.
   PubMed Web of Science ®Google Scholar
• Henze T , Rieckmann P , Toyka KV . Symptomatic treatment of multiple sclerosis. Multiple Sclerosis Therapy Consensus Group (MSTCG) of the German Multiple Sclerosis Society. Eur Neurol. 2006;56(2):78–105.
   PubMed Web of Science ®Google Scholar
• Wang G , Marrie RA , Fox RJ , et al. Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis. Mult Scler Relat Disord. 2018;20:16–21.
   PubMed Web of Science ®Google Scholar
• Fowler CJ , Griffiths D , de Groat WC . The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453–466.
   PubMed Web of Science ®Google Scholar
• Porru D , Campus G , Garau A , et al. Urinary tract dysfunction in multiple sclerosis: is there a relation with disease-related parameters? Spinal Cord. 1997;35(1):33–36.
   PubMed Web of Science ®Google Scholar
• Stoffel JT . Detrusor sphincter dyssynergia: a review of physiology, diagnosis, and treatment strategies. Transl Androl Urol. 2016;5(1):127–135.
   PubMed Web of Science ®Google Scholar
• de Groat WC , Yoshimura N . Afferent nerve regulation of bladder function in health and disease. Handb Exp Pharmacol. 2009; 194 (91–138).
   Google Scholar
• de Sèze M , Raibaut P , Gallien P , et al. Transcutaneous posterior tibial nerve stimulation for treatment of the overactive bladder syndrome in multiple sclerosis: results of a multicenter prospective study. Neurourol Urodyn. 2011;30(3):306–311.
   PubMed Web of Science ®Google Scholar
• Araki I , Matsui M , Ozawa K , et al. Relationship of bladder dysfunction to lesion site in multiple sclerosis. J Urol. 2003;169(4):1384–1387.
   PubMed Web of Science ®Google Scholar
• EAU Guidelines on Neuro-Urology . 2017. [cited 2020 Apr]. Available from: https://uroweb.org/wp-content/uploads/Neuro-Urology-2017-pocket.pdf
   Google Scholar
• Tornic J , Panicker JN . The Management of Lower Urinary Tract Dysfunction in Multiple Sclerosis. Curr Neurol Neurosci Rep. 2018;18(8):54.
   PubMed Web of Science ®Google Scholar
• Marrie RA , Elliott L , Marriott J , et al. Dramatically changing rates and reasons for hospitalization in multiple sclerosis. Neurology. 2014;83(10):929–937.
   PubMed Web of Science ®Google Scholar
• EAU Guidelines on Neuro-Urology . 2016. [cited 2020 Apr]. Available from:https://uroweb.org/wp-content/uploads/EAU-Guidelines-Neuro-urology-2016-1.pdf
   Google Scholar
• de Seze M , Ruffion A , Denys P , et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13(7):915–928.
   PubMed Web of Science ®Google Scholar
• Mahadeva A , Tanasescu R , Gran B . Urinary tract infections in multiple sclerosis: under-diagnosed and under-treated? A clinical audit at a large University Hospital. Am J Clin Exp Immunol. 2014;3(1):57–67.
   PubMedGoogle Scholar
• Ghezzi A , Carone R , Del Popolo G , et al. Recommendations for the management of urinary disorders in multiple sclerosis: a consensus of the Italian Multiple Sclerosis Study Group. Neurol Sci. 2011;32(6):1223–1231.
   PubMed Web of Science ®Google Scholar
• Bright E , Cotterill N , Drake M , et al. Developing and Validating the International Consultation on Incontinence Questionnaire Bladder Diary. Eur Urol. 2014;66(2):294–300.
   PubMed Web of Science ®Google Scholar
• Devillé WLJM , Yzermans JC , van Duijn NP , et al. The urine dipstick test useful to rule out infections. BMC Urology. 2004;4:4.
   PubMedGoogle Scholar
• Rakusa M , Murphy O , McIntyre L , et al. Testing for urinary tract colonization before high-dose corticosteroid treatment in acute multiple sclerosis relapses: prospective algorithm validation. Eur J Neurol. 2013;20(3):448–452.
   PubMed Web of Science ®Google Scholar
• Phe V , Chartier-Kastler E , Panicker JN . Management of neurogenic bladder in patients with multiple sclerosis. Nat Rev Urol. 2016;13(5):275–288.
   PubMed Web of Science ®Google Scholar
• Aharony SM , Lam O , Corcos J . Treatment of lower urinary tract symptoms in multiple sclerosis patients: review of the literature and current guidelines. Can Urol Assoc J. 2017;11(3–4):E110–E5.
   PubMed Web of Science ®Google Scholar
• Tyagi P , Tyagi V , Yoshimura N , et al. Functional role of cannabinoid receptors in urinary bladder. Indian J Urol. 2010;26(1):26–35.
   PubMedGoogle Scholar
• Bragg R , Hebel D , Vouri SM , et al. Mirabegron: a Beta-3 agonist for overactive bladder. Consult Pharm. 2014;29(12):823–837.
   PubMedGoogle Scholar
• Guidelines on pain management un urology . 2010. [cited 2020 Apr]. Available from: https://uroweb.org/wp-content/uploads/Pain-Management-in-Urology-2010.pdf
   Google Scholar
• Schurch B , de Seze M , Denys P , et al. Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol. 2005;174(1):196–200.
   PubMed Web of Science ®Google Scholar
• Apostolidis A , Dasgupta P , Fowler CJ . Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006;49(4):644–650.
   PubMed Web of Science ®Google Scholar
• Cruz F , Herschorn S , Aliotta P , et al. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial. Eur Urol. 2011;60(4):742–750.
   PubMed Web of Science ®Google Scholar
• Ginsberg D , Gousse A , Keppenne V , et al. Phase 3 efficacy and tolerability study of onabotulinumtoxinA for urinary incontinence from neurogenic detrusor overactivity. J Urol. 2012;187(6):2131–2139.
   PubMed Web of Science ®Google Scholar
• Mehnert U , Birzele J , Reuter K , et al. The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study. J Urol. 2010;184(3):1011–1016.
   PubMed Web of Science ®Google Scholar
• Berg WT , Du C , Kim J . Tibial nerve and sacral neuromodulation in the multiple sclerosis patient with voiding dysfunction. Curr Bladder Dysfunct Rep. 2018;13(4):294–300.
   Web of Science ®Google Scholar
• De Ridder D , Ost D , Van der Aa F , et al. Conservative bladder management in advanced multiple sclerosis. Mult Scler J. 2005;11(6):694–699.
   PubMed Web of Science ®Google Scholar
• Wyndaele JJ . Self-intermittent catheterization in multiple sclerosis. Ann Phys Rehabil Med. 2014;57(5):315–320.
   PubMedGoogle Scholar
• Legrand G , Roupret M , Comperat E , et al. Functional outcomes after management of end-stage neurological bladder dysfunction with ileal conduit in a multiple sclerosis population: a monocentric experience. Urology. 2011;78(4):937–941.
   PubMed Web of Science ®Google Scholar
• Westney OL . The neurogenic bladder and incontinent urinary diversion. Urol Clin North Am. 2010;37(4):581–592.
   PubMed Web of Science ®Google Scholar
• Ustinova EE , Fraser MO , Pezzone MA . Cross-talk and sensitization of bladder afferent nerves. Neurourol Urodyn. 2010;29(1):77–81.
   PubMed Web of Science ®Google Scholar